193 related articles for article (PubMed ID: 36087315)
1. Reduction of sporadic and neurofibromatosis type 2-associated vestibular schwannoma growth in vitro and in vivo after treatment with the c-Jun N-terminal kinase inhibitor AS602801.
Dougherty MC; Shibata SB; Clark JJ; Canady FJ; Yates CW; Hansen MR
J Neurosurg; 2023 Apr; 138(4):962-971. PubMed ID: 36087315
[TBL] [Abstract][Full Text] [Related]
2. Contribution of persistent C-Jun N-terminal kinase activity to the survival of human vestibular schwannoma cells by suppression of accumulation of mitochondrial superoxides.
Yue WY; Clark JJ; Fernando A; Domann F; Hansen MR
Neuro Oncol; 2011 Sep; 13(9):961-73. PubMed ID: 21697181
[TBL] [Abstract][Full Text] [Related]
3. A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation.
Gehlhausen JR; Park SJ; Hickox AE; Shew M; Staser K; Rhodes SD; Menon K; Lajiness JD; Mwanthi M; Yang X; Yuan J; Territo P; Hutchins G; Nalepa G; Yang FC; Conway SJ; Heinz MG; Stemmer-Rachamimov A; Yates CW; Wade Clapp D
Hum Mol Genet; 2015 Jan; 24(1):1-8. PubMed ID: 25113746
[TBL] [Abstract][Full Text] [Related]
4. Bentamapimod (JNK Inhibitor AS602801) Induces Regression of Endometriotic Lesions in Animal Models.
Palmer SS; Altan M; Denis D; Tos EG; Gotteland JP; Osteen KG; Bruner-Tran KL; Nataraja SG
Reprod Sci; 2016 Jan; 23(1):11-23. PubMed ID: 26335175
[TBL] [Abstract][Full Text] [Related]
5. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A
Neuro Oncol; 2011 Sep; 13(9):983-99. PubMed ID: 21778190
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of c-Jun N-terminal kinase activity enhances vestibular schwannoma cell sensitivity to gamma irradiation.
Yue WY; Clark JJ; Telisak M; Hansen MR
Neurosurgery; 2013 Sep; 73(3):506-16. PubMed ID: 23728448
[TBL] [Abstract][Full Text] [Related]
7. The novel JNK inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo.
Okada M; Kuramoto K; Takeda H; Watarai H; Sakaki H; Seino S; Seino M; Suzuki S; Kitanaka C
Oncotarget; 2016 May; 7(19):27021-32. PubMed ID: 27027242
[TBL] [Abstract][Full Text] [Related]
8. Gamma Knife radiosurgery for treatment of growing vestibular schwannomas in patients with neurofibromatosis Type 2: a matched cohort study with sporadic vestibular schwannomas.
Kruyt IJ; Verheul JB; Hanssens PEJ; Kunst HPM
J Neurosurg; 2018 Jan; 128(1):49-59. PubMed ID: 28128697
[TBL] [Abstract][Full Text] [Related]
9. Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development.
Fuse MA; Dinh CT; Vitte J; Kirkpatrick J; Mindos T; Plati SK; Young JI; Huang J; Carlstedt A; Franco MC; Brnjos K; Nagamoto J; Petrilli AM; Copik AJ; Soulakova JN; Bracho O; Yan D; Mittal R; Shen R; Telischi FF; Morrison H; Giovannini M; Liu XZ; Chang LS; Fernandez-Valle C
Neuro Oncol; 2019 Mar; 21(4):486-497. PubMed ID: 30615146
[TBL] [Abstract][Full Text] [Related]
10. The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.
Clark JJ; Provenzano M; Diggelmann HR; Xu N; Hansen SS; Hansen MR
Otol Neurotol; 2008 Sep; 29(6):846-53. PubMed ID: 18636037
[TBL] [Abstract][Full Text] [Related]
11. Sulforaphane, a natural component of broccoli, inhibits vestibular schwannoma growth in vitro and in vivo.
Kim BG; Fujita T; Stankovic KM; Welling DB; Moon IS; Choi JY; Yun J; Kang JS; Lee JD
Sci Rep; 2016 Nov; 6():36215. PubMed ID: 27805058
[TBL] [Abstract][Full Text] [Related]
12. The microenvironment in sporadic and neurofibromatosis type II-related vestibular schwannoma: the same tumor or different? A comparative imaging and neuropathology study.
Lewis D; Donofrio CA; O'Leary C; Li KL; Zhu X; Williams R; Djoukhadar I; Agushi E; Hannan CJ; Stapleton E; Lloyd SK; Freeman SR; Wadeson A; Rutherford SA; Hammerbeck-Ward C; Evans DG; Jackson A; Pathmanaban ON; Roncaroli F; King AT; Coope DJ
J Neurosurg; 2020 May; 134(5):1419-1429. PubMed ID: 32470937
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting p21-Activated Kinase Induces Cell Death in Vestibular Schwannoma and Meningioma via Mitotic Catastrophe.
Mercado-Pimentel ME; Miller C; Rolph DN; Villalobos EF; Dunn AM; Mohan PM; Igarashi S; Liu X; Yrun-Duffy M; Patel NK; Read CM; Francis RH; Lane AI; Murugesh S; Jacob A
Otol Neurotol; 2017 Jan; 38(1):139-146. PubMed ID: 27755359
[TBL] [Abstract][Full Text] [Related]
14. A Xenograft Model of Vestibular Schwannoma and Hearing Loss.
Dinh CT; Bracho O; Mei C; Bas E; Fernandez-Valle C; Telischi F; Liu XZ
Otol Neurotol; 2018 Jun; 39(5):e362-e369. PubMed ID: 29557843
[TBL] [Abstract][Full Text] [Related]
15. The molecular biology and novel treatments of vestibular schwannomas.
Fong B; Barkhoudarian G; Pezeshkian P; Parsa AT; Gopen Q; Yang I
J Neurosurg; 2011 Nov; 115(5):906-14. PubMed ID: 21800959
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma.
Sagers JE; Beauchamp RL; Zhang Y; Vasilijic S; Wu L; DeSouza P; Seist R; Zhou W; Xu L; Ramesh V; Stankovic KM
Sci Rep; 2020 Mar; 10(1):4211. PubMed ID: 32144278
[TBL] [Abstract][Full Text] [Related]
17. Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells.
Lee TX; Packer MD; Huang J; Akhmametyeva EM; Kulp SK; Chen CS; Giovannini M; Jacob A; Welling DB; Chang LS
Eur J Cancer; 2009 Jun; 45(9):1709-20. PubMed ID: 19359162
[TBL] [Abstract][Full Text] [Related]
18. p75NTR is highly expressed in vestibular schwannomas and promotes cell survival by activating nuclear transcription factor κB.
Ahmad I; Yue WY; Fernando A; Clark JJ; Woodson EA; Hansen MR
Glia; 2014 Oct; 62(10):1699-712. PubMed ID: 24976126
[TBL] [Abstract][Full Text] [Related]
19. ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy.
Doherty JK; Ongkeko W; Crawley B; Andalibi A; Ryan AF
Otol Neurotol; 2008 Jan; 29(1):50-7. PubMed ID: 18199957
[TBL] [Abstract][Full Text] [Related]
20. AS602801 treatment suppresses breast cancer metastasis to the brain by interfering with gap-junction communication by regulating Cx43 expression.
Yang Z; Yang L; Zhang J; Qian C; Zhao Y
Drug Dev Res; 2024 Feb; 85(1):e22124. PubMed ID: 37859299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
